We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+33.77%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.6B
AUM Growth
+$3.41B
Cap. Flow
-$91.9M
Cap. Flow %
-0.59%
Top 10 Hldgs %
85.51%
Holding
100
New
7
Increased
16
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$48.4M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.8M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$23.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$11.1M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$115M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.5M
3
ARRY
Array Biopharma Inc
ARRY
+$25M
4
SLDB icon
Solid Biosciences
SLDB
+$15.8M
5
NVAX icon
Novavax
NVAX
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 99.44%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
76
Intellia Therapeutics
NTLA
$1.8B
$2.19M 0.01%
128,538
– –
GTHX
77
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.11M 0.01%
127,236
– –
CTMX icon
78
CytomX Therapeutics
CTMX
$715M
$2.09M 0.01%
+194,377
New +$2.87M
HARP
79
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.03M 0.01%
+21,429
New +$2.82M
FOMX
80
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.87M 0.01%
498,189
– –
CNST
81
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$1.81M 0.01%
133,333
– –
GLMD icon
82
Galmed Pharmaceuticals
GLMD
$4.48M
$1.76M 0.01%
150
– –
RCUS icon
83
Arcus Biosciences
RCUS
$3.86B
$1.52M 0.01%
121,534
– –
MTEM
84
DELISTED
Molecular Templates, Inc.
MTEM
$1.48M 0.01%
16,949
– –
ADMS
85
DELISTED
Adamas Pharmaceuticals
ADMS
$1.23M 0.01%
172,630
– –
CFRX
86
DELISTED
ContraFect Corporation
CFRX
$1.16M 0.01%
3,643
-5,298
-59% -$2.3M
INFI
87
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.09M 0.01%
580,400
– –
AFMD
88
DELISTED
Affimed
AFMD
$840K 0.01%
20,000
– –
FLGT icon
89
Fulgent Genetics
FLGT
$548M
$744K ﹤0.01%
125,000
– –
AQST icon
90
Aquestive Therapeutics
AQST
$585M
$688K ﹤0.01%
99,600
– –
VIRX
91
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$676K ﹤0.01%
15,905
– –
DVAX
92
DELISTED
Dynavax Technologies
DVAX
$548K ﹤0.01%
75,000
– –
TRIL
93
DELISTED
Trillium Therapeutics Inc.
TRIL
$333K ﹤0.01%
505,262
– –
AIXC
94
AIxCrypto Holdings Inc
AIXC
$22.7M
$244K ﹤0.01%
22
– –
NVAX icon
95
Novavax
NVAX
$1.47B
– –
-235,916
Closed -$8.68M
SLDB icon
96
Solid Biosciences
SLDB
$997M
– –
-39,192
Closed -$15.8M
TARA icon
97
Protara Therapeutics
TARA
$228M
– –
-7,465
Closed -$678K
GNMX
98
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-3,950,419
Closed -$2.77M
1 2 3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2019 Portfolio in Review

As of Q1 2019, Julian Baker held 100 positions worth $15.6B, up 28% from $12.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q1 2019 filing shows 7 new, 16 increased, 6 reduced and 4 closed positions. Its largest new stake was Axsome Therapeutics: 1,200,000 shares worth $17.1M. The largest sale was Genomic Health, Inc., an estimated $115M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q1 2019 buy was Axsome Therapeutics: 1,200,000 shares worth $17.1M.
  • Julian Baker added most to Ascendis Pharma A/S in Q1 2019, an estimated $48.4M increase.
  • Julian Baker's biggest Q1 2019 reduction was Genomic Health, Inc., cutting an estimated $115M.
  • Julian Baker fully exited Solid Biosciences in Q1 2019, selling an estimated $15.8M.
  • Julian Baker's ten largest holdings make up 86% of its $15.6B portfolio in Q1 2019.
  • Julian Baker opened 7 new positions and closed 4 in Q1 2019.
  • Julian Baker's portfolio value rose 28% quarter-over-quarter to $15.6B.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.